spacer
home > ict > spring 2021 > the biotech journey: from lab development to clinical delivery
PUBLICATIONS
International Clinical Trials

The Biotech Journey: From Lab Development to Clinical Delivery



Biotechnology and emerging biopharmaceutical companies face countless challenges as they look to advance their drug to market. From the increasing clinical trial costs through each phase of development, to the fierce asset and patient competition ubiquitous within each stage, it can often feel like a mad dash to the finish line. Furthermore, with the COVID-19 pandemic jump-starting rapid global modernisation of clinical trials, coupled with increased investment in the biopharma sector, there is mounting pressure to have technological solutions in place to recruit and retain patients and drive innovation, efficiency, and speed.

To increase the probability of efficient and effective global trials, as well as to bring value to each phase of drug development towards commercialisation, many biotech companies engage CROs for support. Considerations for selecting a partner that can de-risk the challenges of bringing a drug to market are paramount for the biopharma sector.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Erin Finot, MBA, is Vice President of Immuno- Oncology at IQVIA Biotech. She is responsible for leading the team’s strategic direction to help sponsors focused on immuno-oncology trial programmes meet their goals. As advancements in immuno-oncology continue to transform cancer care, Erin guides sponsors through a dynamic landscape with more than 20 years of experience in global clinical research and drug development processes, including adoptive cellular trials. Erin has a Bachelor’s in Biology from the University of California, Berkeley, US, and a Master’s degree in Immunology from the University of Virginia, US, providing a solid foundation for her therapeutic expertise.
Print this page
Send to a friend
Privacy statement
News and Press Releases

IBM Research and Arctoris Accelerate Closed Loop Drug Discovery with AI and Cloud

Oxford and Zurich – 13 September 2021 – Life Science Newswire – Today, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement